LODOCO (colchicine)
Cardiovascular Disease Prevention
ApprovedActive
Key Facts
About Agepha Pharma
AGEPHA Pharma is a private, commercial-stage European pharmaceutical company with a diversified portfolio spanning prescription drugs, OTC products, and supplements. Its strategic milestones include the 2023 U.S. FDA approval of LODOCO (colchicine) for cardiovascular disease and the expansion of its ophthalmic portfolio through acquisitions. With products available in 47 countries and a family-owned operational model, the company combines a legacy of trust with targeted innovation in specific therapeutic areas.
View full company profileTherapeutic Areas
Other Cardiovascular Disease Prevention Drugs
| Drug | Company | Phase |
|---|---|---|
| Atherosclerotic Cardiovascular Disease (ASCVD) Trial | Clinical Investigation Specialists | Not Specified |